Abstract
Methotrexate (MTX) and 6-mercaptopurine (6-MP) are widely used in the maintenance treatment of acute lymphoblastic leukemia (ALL) in children. Based on their biochemical interactions there are reasons to support a combination therapy of both drugs. MTX binds tightly to dihydrofolate reductase, the enzyme that catalyses the reduction of dihydrofolate to tetrahydrofolate. Tetrahydrofolate coenzymes are required for one-carbon transfer reactions in purine de novo synthesis and thymidylate biosynthesis (Figure 1). As a consequence a purine-less and a thymidylate-less state will occur, ultimately resulting in inhibition of DNA biosynthesis [1–10].
Keywords
- Dihydrofolate Reductase
- Raji Cell
- Purine Biosynthesis
- Performance Liquid Chromatographic Assay
- Triphosphate Pool
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sartorelli AC, Le Page GA: Amethopterin on the purine biosynthesis of susceptible and resistant TA3 ascites cells. Cancer Res 18: 1336–1339, 1958.
Werkheiser WC: The biochemical, cellular and pharmacological action and effects of the folic acid antagonists. Cancer Res 23: 1277–1285, 1963.
Borsa J, Whitmore GF: Studies relating to the mode of action of methotrexate. II. Studies in sites of action on L-cells in vitro. Mol Pharmacol 5: 303–317, 1969.
Cohen SS: On the nature of thymidineless death. Ann NY Acad Sci 186: 292–301, 1971.
Hryniuk WM: The mechanism of action of methotrexate in cultured L5178Y leukemia cells. Cancer Res 35: 1085–1092, 1975.
Hryniuk WM, Brox LW, Henderson JF, Tamaoki T: Consequences of methotrexate inhibition of purine biosynthesis in L5178Y cells. Cancer TCancer Res 35: 1427–1532, 1975.
White JC, Loftfield S, Goldman ID: The mechanism of action of methotrexate. III. Requirement of free intra-cellular methotrexate for maximal suppression of 14C-formate incorporation into nucleic acids and protein. Mol Pharmacol 11: 387–297, 1975.
Moran RG, Mulkins M, Heidelberger C: Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc Natl Acad Sci USA 76: 5924–5928, 1979.
Cha S, Kim SY, Kornstein SG, Kantoff PW, Im KH, Nagub FHM: Kinetic parameters of dihydrofolate reductase inhibited by methotrexate, an example of equilibrium study. Biochem Pharmacol 30: 1507–1515, 1981.
Chabner BA: Methotrexate. In: Pharmacologic principles of cancer treatment. Chabner. Saunders, Philadelphia, 229–255, 1982.
Buesa-Perez JM, Leyva A, Pinedo HM: Effect of methotrexate on 5-phosphoribosyl-l-pyrophosphate levels in LI210 leukemia cells in vitro. Cancer Res 40: 139–144, 1980.
De Abreu RA, Van Baal JM, Bakkeren JAJM, De Bruyn CHMM, Schetlen EDAM: High-performance liquid chromatographic assay for identification and quantitation of nucleotides in lymphocytes and malignant lymphoblasts. J Chromatogr 227: 45–52, 1982.
Hillen HFP, Wessels J, Haanen C: Bone marrow proliferation patterns determined by pulse photocytometry in acute myeloblasts leukemia. Lancet ii: 609–611, 1975.
Skoog KL, Bjursell G, Nordenskjold BA: Cellular deoxyribonucleotide triphosphate pool levels and DNA synthesis. Adv Enzyme Regul 12: 345–354, 1974.
Taylor IW, Slowiaczek P, Francis PR, Tattersall MHN: Biochemical and cell cycle pertubations in methotrexate-treated cells. Mol Pharmacol 21: 204–210, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Martinus Nijhoff Publishers, Dordrecht
About this chapter
Cite this chapter
De Abreu, R.A., Bökkerink, J.P.M., Bakker, M.A.H., Hulscher, T.W., Van Baal, J.M. (1987). The effect of methotrexate on purine and pyrimidine deoxyribonucleoside triphosphate pools and on cell viability and cell-phase distribution in malignant human T- and B-lymphoblasts. In: Poplack, D.G., Massimo, L., Cornaglia-Ferraris, P. (eds) The Role of Pharmacology in Pediatric Oncology. Developments in Oncology, vol 44. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-4267-7_14
Download citation
DOI: https://doi.org/10.1007/978-94-009-4267-7_14
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-8395-9
Online ISBN: 978-94-009-4267-7
eBook Packages: Springer Book Archive